Abstract
Introduction To eliminate the hepatitis C virus (HCV) by 2030, Canada must adopt a micro-elimination approach targeting priority populations, including gay, bisexual, and other men who have sex with men (MSM). HCV prevalence and risk factors among MSM populations are context-dependent, and accurately describing these indicators at the local level is essential if we want to design appropriate, targeted prevention and treatment interventions. We aimed first to estimate and investigate temporal trends in HCV seroprevalence between 2005-2018 among Montréal MSM, and then to identify the socio-economic, behavioural, and biological factors associated with HCV exposure among this population.
Methods We used data from three bio-behavioural cross-sectional surveys conducted among Montréal MSM in 2005 (n=1,795), 2009 (n=1,258), and 2018 (n=1,086). To ensure comparability of seroprevalence estimates across time, we standardized the 2005 and 2009 time-location samples to the 2018 respondent-driven sample. Time trends overall and stratified by HIV status, history of injection drug use (IDU), and age were examined. Modified Poisson regression analyses with generalized estimating equations were used to identify factors associated with HCV seropositivity pooling all surveys. We used multiple imputation by chained equations for all missing values.
Results Standardized HCV seroprevalence among all MSM remained stable from 7% (95% confidence interval (CI): 3-10%) in 2005, to 8% (95%CI: 1-9%) in 2009, and 8% (95%CI: 4-11%) in 2018. This apparent stability hides diverging temporal trends in seroprevalence between age groups, with a decrease among MSM <30 years old, and an increase among MSM aged ≥45 years. History of IDU was the strongest predictor for HCV seropositivity (adjusted prevalence ratio: 8.0; 95%CI: 5.5-11.5), and no association was found between HCV seroprevalence and the sexual risk factors studied (condomless anal sex with men of serodiscordant/unknown HIV status, number of sexual partners, and group sex), nor with biological markers of syphilis.
Conclusions HCV seroprevalence remained stable among Montréal MSM between 2005-2018. Unlike other settings where HCV infection was strongly associated with sexual risk factors among MSM subgroups, IDU was the preeminent risk factor for HCV seropositivity. Understanding the intersection of IDU contexts, practices, and populations is essential to prevent HCV transmission among MSM.
Competing Interest Statement
C.L.D., G.L., D.G., and N.L. have no conflicts of interest to declare. J.C. has received research grant funding from Gilead Sciences, Merck Canada, and ViiV Healthcare. He also received travel support and honoraria for advisory work from Gilead Sciences, Merck Canada and ViiV Healthcare. M.K. reports grants for investigator-initiated studies from ViiV Healthcare, Merck, and Gilead; research grants from Janssen; personal fees from ViiV Healthcare, Bristol-Myers Squibb, AbbVie, and Gilead, all outside the submitted work. M.M.-G. reports grant funding from Gilead Sciences.
Funding Statement
The Argus surveys were funded by the Institut national de sante publique du Quebec and the Public Health Agency of Canada. Engage is funded by the Canadian Institutes of Health Research, the Canadian Foundation for AIDS Research, and the Ontario HIV Treatment Network. C.L.D. received a Ph.D. trainee fellowship from the Canadian Network on Hepatitis C. The Canadian Network on Hepatitis C is funded by a joint initiative of the Canadian Institutes of Health Research (NHC-142832) and the Public Health Agency of Canada. C.L.D. also received a doctoral training award from the Fond de Recherche du Quebec – Sante. M.K. is supported by a Tier I Canada Research Chair. M.M.-G.’s research program is funded by a career award from the Fonds de recherche du Quebec – Sante. The authors thank the Reseau de recherche en sante des populations du Quebec (RRSPQ) for its contribution to the financing of this publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
List of abbreviations
- aPR
- adjusted prevalence ratio
- CAD
- Canadian dollars
- CAS
- condomless anal sex
- CI
- confidence interval
- HCV
- hepatitis C virus
- HIV
- human immunodeficiency virus
- MSM
- gay, bisexual, and other men who have sex with men
- P6M
- past six months
- RDS
- respondent-driven sampling
- RERI
- relative excess risk due to interaction
- RNA
- ribonucleic acid
- WHO
- World Health Organization
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.